Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28802880 | 0.88 | LMNA (1.00) | RAB9ALMNAALDH1A1SMN1; SMN2HTT | |
| SCHEMBL7277682 | 0.88 | LMNA (0.78) | RAB9ALMNAALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL19463937 | 0.78 | RAB9A (0.63) | RAB9ALMNAALDH1A1KDM4EMAPK1 | |
| SCHEMBL19642599 | 0.75 | LMNA (0.61) | RAB9ALMNAALDH1A1SMN1; SMN2HTT | |
| SCHEMBL20338306 | 0.75 | RAB9A (0.60) | RAB9ALMNAALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL1754736 | 0.74 | GPR119 (0.61) | RAB9ALMNAALDH1A1SMN1; SMN2HTT | |
| SCHEMBL8480469 | 0.73 | LMNA (0.59) | RAB9ALMNAALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL19463838 | 0.73 | RAB9A (0.57) | RAB9ALMNAALDH1A1KDM4EMAPK1 | |
| SCHEMBL20471436 | 0.73 | LMNA (0.76) | RAB9ALMNAALDH1A1SMN1; SMN2HTT | |
| SCHEMBL10777449 | 0.73 | RAB9A (0.56) | RAB9ALMNAALDH1A1SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101486683-B | Pyridazinone and triazinone compounds and their use as pharmaceutical formulations | Sanitary Material R&D Management Co.,Ltd. (JP) | 2011-12-21 | — | — | CN | disclosed |
| CN-101486683-A | Pyridazinone and triazinone compounds and their use as pharmaceutical formulations | EISAI R&D MAN CO LTD (JP) | 2009-07-22 | — | — | CN | disclosed |
| CN-100473647-C | Pyridazinone and triazinone compounds and their use as pharmaceutical formulations | EISAI CO LTD (JP) | 2009-04-01 | — | — | CN | disclosed |
| US-20060189622-A1 | Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| US-20030225081-A1 | Pyridazinones and triazinones and medicinal use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-12-04 | — | — | US | disclosed |
| CN-1458924-A | Pyridazinone and triazinone compounds and their use as pharmaceutical formulations | EISAI CO LTD (JP) | 2003-11-26 | — | — | CN | disclosed |
| EP-1319659-A1 | PYRIDAZINONES AND TRIAZINONES AND MEDICINAL USE THEREOF | Eisai Co., Ltd. (JP) | 2003-06-18 | — | — | EP | disclosed |
| US-4631280-A | Pyridazine derivatives having a psychotropic action, and medicaments in which they are present | SANOFI (FR) | 1986-12-23 | — | — | US | disclosed |
| US-4565814-A | Pyridazine derivatives having a psychotropic action and compositions | SANOFI (FR) | 1986-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225081-A1 | Pyridazinones and triazinones and medicinal use thereof | GRIK1, GRIK3, GRIK2 | RAB9A 4582/4885LMNA 2726/4885ALDH1A1 1550/4885 |
| US-20060189622-A1 | Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations | GRIK3, GRIK1, GRIK2 | RAB9A 4719/4885LMNA 2181/4885ALDH1A1 2206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.